Influence of substitution pattern and cation binding on conformation and activity in heparin derivatives

Glycobiology

Volumn 17, Issue 9, 2007, Pages 983-993

  Rudd, Timothy R ^a   Guimond, Scott E ^a   Skidmore, Mark A ^a   Duchesne, Laurence ^a   Guerrini, Marco ^b   Torri, Giangiacomo ^b   Cosentino, Cesare ^b   Brown, Alan ^c   Clarke, David T ^c   Turnbull, Jeremy E ^a   Fernig, David G ^a   Yates, Edwin A ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b Istituto di Ricerche Chimiche e Biochimiche G Ronzoni   (Italy)

^c DARESBURY LABORATORY   (United Kingdom)

Author keywords

Cations; Fibroblast growth factor; Heparan sulfate; Heparin; Synchrotron radiation circular dichroism

Indexed keywords

CALCIUM ION; CATION; COPPER ION; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 1C; HEPARAN SULFATE; HEPARIN DERIVATIVE; IRON; MAGNESIUM ION; MANGANESE; POTASSIUM ION; SODIUM ION; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BIOLOGICAL ACTIVITY; CARBOHYDRATE ANALYSIS; CELL ASSAY; CIRCULAR DICHROISM; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; GLYCOBIOLOGY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; NUCLEAR OVERHAUSER EFFECT; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; SYNCHROTRON RADIATION; TREND STUDY;

ANIMALS; CATIONS; CELL PROLIFERATION; CIRCULAR DICHROISM; HEPARIN; HUMANS; IONS; MAGNETIC RESONANCE SPECTROSCOPY; MICE; MOLECULAR CONFORMATION; POLYSACCHARIDES; PRINCIPAL COMPONENT ANALYSIS; STRUCTURE-ACTIVITY RELATIONSHIP; SWINE; SYNCHROTRONS;

EID: 34548810245     PISSN: 09596658     EISSN: 14602423     Source Type: Journal    
DOI: 10.1093/glycob/cwm062     Document Type: Article

References (65)

1. Alessandri G, Raju K, Gullino PM. 1983. Selective mobilization of capillary endothelium in vitro and induction of angiogenesis in vivo by heparin-copper complex. P Am Assoc Canc Res. 24:22-22.
2. Alessandri G, Raju K, Gullino PM. 1984. Angiogenesis in vivo and selective mobilization of mapillary endothelium in vitro by heparin-copper complex. Microcirc Endoth Lym. 1(3):329-346.
3. 2+: A model study with a synthetic heparin-like hexasaccharide. Isr J Chem. 40(3-4):289-299.
4. Arndt ER, Stevens ES. 1993. Vacuum-ultraviolet circular-dichroism studies of simple saccharides. J Am Chem Soc. 115(17):7849-7853.
5. Arndt ER, Stevens ES. 1996. Vacuum ultraviolet circular dichroism of gellan-family polymer films from water and dimethyl sulfoxide. Carbohydr Res. 280(1):15-26.
6. Bell CF. 1977. Principles and applications of metal chelation. Oxford University Press, Oxford, UK.
7. Buffington LA, Pysh ES, Chakrabarti B, Balazs EA. 1977. Far UV circular-dichroism of N-acetylglucosamine, glucuronic acid, and hyaluronic-acid. J Am Chem Soc. 99(6):1730-1734.
8. Capila I, Linhardt RJ. 2002. Heparin - protein interactions. Angew Chem Int Ed. 41(3):391-412.
9. Chung MCM, Ellerton NF. 1976. Viscosity at low shear and circular-dichroism studies of heparin. Biopolymers. 15(7):1409-1423.
10. Davies JA, Yates EA, Turnbull JE. 2003. Structural determinants of heparan sulphate modulation of GDNF signalling. Growth Factors. 21(3-4):109-119.
11. Dayie KT, Wagner G. 1994. Relaxation-rate measurements forN-15-H-1 groups with pulsed-field gradients and preservation of coherence pathways. J Magn Reson Ser A. 111(1):121-126.
12. Delehedde M, Lyon M, Sergeant N, Rahmoune H, Fernig DG. 2001. Proteoglycans: Pericellular and cell surface multireceptors that integrate external stimuli in the mammary gland. J Mammary Gland Biol Neoplasia. 6(3):253-273.
13. Ferro DR, Provasoli A, Ragazzi M, Casu B, Torri G, Bossennec V, Perly B, Sinay P, Petitou M, Choay J. 1990. Conformer populations of L-iduronuc acid residues in glycosaminoglycan sequences. Carbohydr Res. 195:157-167.
14. Ferro DR, Provasoli A, Ragazzi M, Torri G, Casu B, Gatti G, Jacquinet JC, Sinay P, Petitou M, Choay J. 1986. Evidence for conformational equilibrium of the sulphated L-iduronate residue in heparin and in synthetic heparin monosaccharides and oligosaccharides - NMR and force-field studies. J Am Chem Soc. 108(21):6773-6778.
15. Gabizon R, Meiner Z, Halimi M, Bensasson SA. 1993. Heparin-like molecules bind differentially to prion-proteins and change their intracellular metabolic-fate. J Cell Physiol. 157(2):319-325.
16. Gallagher JT. 2001. Heparan sulphate: Growth control with a restricted sequence menu. J Clin Invest. 108(3):357-361.
17. Gallagher JT. 2006. Multiprotein signalling complexes: Regional assembly on heparan sulphate. Biochem Soc Trans. 34:438-441.
18. Goldner M, Mingot N, Emond JP, Dublanchet A. 1997. Influence of different levels of redox potential on fermentative products formed by bacteroides fragilis. Clin Infect Dis. 25:S147-S150.
19. Goodman VL, Brewer GJ, Merajver SD. 2005. Control of copper status for cancer therapy. Curr Cancer Drug Targets. 5(7):543-549.
20. 2+-heparin interaction studied by polarimetry. Biochem J. 283:243-246.
21. Grootenhuis PDJ, Westerduin P, Meuleman D, Petitou M, Vanboeckel CAA. 1995. Rational design of synthetic heparin analogs with tailor-made coagulation-factor inhibitory activity. Nat Struct Biol. 2(9):736-739.
22. Guimond S, Maccarana M, Olwin BB, Lindahl U, Rapraeger AC. 1993. Activating and inhibitory heparin sequences for Fgf-2 (Basic Fgf) - Distinct Requirements for Fgf-1, Fgf-2, and Fgf-4. J Biol Chem. 268(32):23906-23914.
23. Guimond SE, Turnbull JE, Yates EA. 2006. Engineered bio-active polysaccharides from heparin. Macromol Biosci. 6:681-686.
24. Hricovini M, Guerrini M, Torri G, Casu B. 1997. Motional properties of E. coli polysaccharide K5 in aqueous solution analyzed by NMR relaxation measurements. Carbohydr Res. 300(1):69-76.
25. Hricovini M, Guerrini M, Torri G, Piani S, Ungarelli F. 1995. Conformational-analysis of heparin epoxide in aqueous-solution - an NMR relaxation study. Carbohydr Res. 277(1):11-23.
26. Hricovini M, Tvaroska I. 1990. Conformational dependence of the one-bond carbon proton coupling-constants in oligosaccharides. Magn Res Chem. 28(10):862-866.
27. Ilan N, Elkin M, Vlodavsky I. 2006. Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Int J Biochem Cell Biol. 38(12):2018-2039.
28. Irie A, Yates EA, Turnbull JE, Holt CE. 2002. Specific heparan sulphate structures involved in retinal axon targeting. Development. 129(1):61-70.
29. Jahn H, Teller E. 1937. Stability of polyatomic molecules in degenerate electronic states. I. Orbital Degeneracy. Proc R Soc A. 161(905):220-235.
30. Jakobson AM, Hahnenberger R. 1991. Antiangiogenic effect of heparin and other sulphated glycosaminoglycans in the chick-embryo chorioallantoic membrane. Pharmacol Toxicol. 69(2):122-126.
31. Kay LE, Nicholson LK, Delaglio F, Bax A, Torchia DA. 1992. Pulse sequences for removal of the effects of cross-correlation between dipolar and chemical-shift anisotropy relaxation mechanism on the measurement of heteronuclear T1 and T2 values in proteins. J Magn Reson. 97(2):359-375.
32. Landt M, Hortin GL, Smith CH, Mcclellan A, Scott MG. 1994. Interference in ionized calcium measurements by heparin salts. Clin Chem. 40(4):565-570.
33. Lowndes SA, Harris AL. 2005. The role of copper in tumour angiogenesis. J Mammary Gland Biol. 10(4):299-310.
34. Morris ER, Rees DA, Sanderson GR, Thom D. 1975. Conformation and circular dichroism of uronic acid residues in glycosides and polysaccharides. J Chem Soc, Perkin Trans 2(13):1418-1425.
35. Mulloy B, Forster MJ, Jones C,Davies DB. 1993. NMR and molecular-modeling studies of the solution conformation of heparin. Biochem J. 293:849-858.
36. Mulloy B, Forster MJ, Jones C, Drake AF, Johnson EA, Davies DB. 1994. The effect of variation of substitution on the solution conformation of heparin - a spectroscopic and molecular modeling study. Carbohydr Res. 255:1-26.
37. Ornitz DM, Xu JS, Colvin JS, McEwen DG, MacArthur CA, Coulier F, Gao GX, Goldfarb M. 1996. Receptor specificity of the fibroblast growth factor family. J Biol Chem. 271(25):15292-15297.
38. Parish CR. 2006. The role of heparan sulphate in inflammation. Nature Rev Immun. 6(9):633-643.
39. Patey SJ, Edwards EA, Yates EA, Turnbull JE. 2006. Heparin derivatives as inhibitors of BACE-1, the Alzheimer's beta-secretase, with reduced activity against factor Xa and other proteases. J Med Chem. 49(20):6129-6132.
40. Powell AK, Yates EA, Fernig DG, Turnbull JE. 2004. Interactions of heparin/heparan sulphate with proteins: Appraisal of structural factors and experimental approaches. Glycobiology. 14(4):17r-30r.
41. Rabenstein DL, Robert JM, Peng J. 1995. Multinuclear magnetic resonance studies of the interaction of inorganic cations with heparin. Carbohydr Res. 278(2):239-256.
42. Ragazzi M, Ferro DR, Perly B, Sinay P, Petitou M, Choay J. 1990. Conformation of the pentasaccharide corresponding to the binding site of heparin for antithrombin III. Carbohydr Res. 195:169-185.
43. Rej RN, Holme KR, Perlin AS. 1990. Marked stereoselectivity in the binding of copper ions by heparin - contrasts with the binding of gadolinium and calcium-ions. Carbohydr Res. 207(2):143-152.
44. Rickard SM, Mummery RS, Mulloy B, Rider CC. 2003. The binding of human glial cell line-derived neurotrophic factor to heparin and heparan sulphate: Importance of 2-O-sulphate groups and effect on its interaction with its receptor, GFR alpha 1. Glycobiology. 13(6):419-426.
45. Scholefield Z, Yates EA, Wayne G, Amour A, McDowell W, Turnbull JE. 2003. Heparan sulphate regulates amyloid precursor protein processing by BACE1, the Alzheimer's beta-secretase. J Cell Biol. 163(1):97-107.
46. Skidmore MA, Guimond SE, Dumax-Vorzet AF, Atrih A, Yates EA, Turnbull JE. 2006. High sensitivity separation and detection of heparan sulphate disaccharides. J Chromatogr A. 1135(1):52-56.
47. Stevens ES, Morris ER, Rees DA, Sutherland JC. 1985. Synchrotron lightsource applied to measuring the vacuum ultraviolet circular-dichroism of heparin. J Am Chem Soc. 107(10):2982-2983.
48. Stone AL. 1985. Far-ultraviolet circular-dichroism and uronic-acid components of anticoagulant decasaccharide, dodecasaccharide, tetradecasaccharide, and octadecasaccharide heparin fractions. Arch Biochem Biophys. 236(1):342-353.
49. Stone AL, Constant G, Sotsky SM, Dekaban A. 1970. Optical rotatory dispersion of mucopolysaccharides. 4. Optical rotatory dispersion and circular dichroism of glycosaminoglycans and heparan sulphate fractions from urine of patients with mucopolysaccharidosis (Hurler-Syndrome). Biochim Biophys Acta. 222(1):79-89.
50. Stringer SE. 2006. The role of heparan sulphate proteoglycans in angiogenesis. Biochem Soc Trans. 34:451-453.
51. Tiwari V, Clement C, Ding X, Valyi-Nagy T, Yue BYJT, Jian L, Shukla D. 2006. Role for 3-O-sulphated heparan sulphate as the receptor for herpes simplex virus type 1 entry into primary human corneal fibroblasts. J Virol. 80(18):8970-8980.
52. Turnbull JE, Powell A, Guimond SE. 2001. Heparan sulphate: Decoding a dynamic multifunction nal cell regulator. Trends Cell Biol. 11(2):75-82.
53. Trumbo P, Schlicker S, Yates AA, Poos M. 2002. Dietary reference intakes for energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein and amino acids. J Am Diet Assoc. 102(11):1621-1630.
54. Tvaroska I, Taravel FR. 1992. One-bond carbon proton coupling-constants-angular-dependence in beta-linked oligosaccharides. J Biomol NMR. 2(5):421-430.
55. Varela-Nallar L, Toledo EM, Chacon MA, Inestrosa NC. 2006. The functional links between prion protein and copper. Biol Res. 39(1):39-44.
56. Villanueva GB, Allen N. 1984. Effect of heparin modification on its circular-dichroism spectrum. Biochem Biophys Res Commun. 123(3):973-980.
57. Vogt AM, Winter G, Wahlgren M, Spillmann D. 2004. Heparan sulphate identified on human erythrocytes: A plasmodium falciparum receptor. Biochem J. 381:593-597.
58. Wadstrom T, Ljungh A. 1999. Glycosaminoglycan-binding microbial proteins in tissue adhesion and invasion: Key events in microbial pathogenicity. J Med Microbiol. 48(3):223-233.
59. Wallace BA. 2000. Conformational changes by synchrotron radiation circular dichroism spectroscopy. Nat Struct Biol. 7(9):708-709.
60. Westling C, Lindahl U. 2002. Location of N-unsubstituted glucosamine residues in heparan sulphate. J Biol Chem. 277(51):49247-49255.
61. Yates EA, Guimond SE, Turnbull JE. 2004. Highly diverse heparan sulphate analogue libraries: Providing access to expanded areas of sequence space for bioactivity screening. J Med Chem. 47(1):277-280.
62. Yates EA, Rudd TR, Ducesne L, Skidmore MA, Nichols RJ, Clarke DT, Fernig DG. 2007. Revealing the hidden dimensions of GAGs in solution and in protein complexes with saccharide libraries, FTIR and SRCD. In: Samson C, Markham O, editors. Glycobiology. Scion, Bloxham, UK.
63. Yates EA, Santini F, De Cristofano B, Payre N, Cosentino C, Guerrini M, Naggi A, Torri G, Hricovini M. 2000. Effect of substitution pattern on H-1, C-13 NMR chemical shifts and (1)J(CH) coupling constants in heparin derivatives. Carbohydr Res. 329(1):239-247.
64. Yates EA, Santini F, Guerrini M, Naggi A, Torri G, Casu B. 1996. H-1 and C-13 NMR spectral assignments of the major sequences of twelve systematically modified heparin derivatives. Carbohydr Res. 294:15-27.
65. Yates EA, Terry CJ, Rees C, Rudd TR, Duchesne L, Skidmore MA, Levy R, Thanh NTK, Nichols RJ, Clarke DT, Fernig DG. 2006. Protein-GAG interactions: New surface-based techniques, spectroscopies and nanotechnology probes. Biochem Soc Trans. 34:427-430.